Triazolam
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Triazolam
Triazolam: Known uses and market status in Canada
Summary
All candidates that the TxGNN model produced for Triazolam (score ≥ 0.99) and that can be traced to a source are already known uses. There is therefore currently no new predicted indication for this drug. The single known use is insomnia-related and falls in the same disease category as an approved indication.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| sleep disorder, initiating and maintaining sleep | insomnia |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 00808571 | TRIAZOLAM | Valid |
Safety Considerations
Product-label warnings and contraindications are not available in the data compiled for this report. Please refer to the package insert for these.
- Contraindication-related conditions (from the knowledge graph, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, kidney disease, liver disease, gallbladder disease, psychotic disorder, schizophreniform disorder, schizoaffective disorder, mental disorder, obstructive sleep apnea syndrome, sleep apnea syndrome, congenital central hypoventilation syndrome, myasthenia gravis (including adult-onset), neuromuscular junction disease, substance-related disorder, and substance abuse/dependence.
- Drug Interactions: 100 interactions were found in total. The first 20 listed include:
- Major: morphine (additive central nervous system and respiratory depression is the expected concern).
- Moderate: ranitidine, bupropion, aprepitant, omeprazole, cimetidine, clarithromycin, dronabinol, eluxadoline, teduglutide, nabilone, metoclopramide, miconazole, clotrimazole.
- Minor: dexamethasone, betamethasone, magnesium oxide, prednisone, aluminum hydroxide, calcium carbonate.
- Literature-noted risks: rebound insomnia after stopping, residual effects on driving, tolerance and dependence concerns with benzodiazepines, and special caution in older adults.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.